[go: up one dir, main page]

CY1120220T1 - Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση - Google Patents

Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση

Info

Publication number
CY1120220T1
CY1120220T1 CY20181100387T CY181100387T CY1120220T1 CY 1120220 T1 CY1120220 T1 CY 1120220T1 CY 20181100387 T CY20181100387 T CY 20181100387T CY 181100387 T CY181100387 T CY 181100387T CY 1120220 T1 CY1120220 T1 CY 1120220T1
Authority
CY
Cyprus
Prior art keywords
cells
methods
infection
status
iii
Prior art date
Application number
CY20181100387T
Other languages
English (en)
Inventor
Ajit Lalvani
Katrina Mary POLLOCK
Graham Taylor
Hilary Sian WHITWORTH
Original Assignee
Mjo Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjo Innovation Limited filed Critical Mjo Innovation Limited
Publication of CY1120220T1 publication Critical patent/CY1120220T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Παρέχονται μέθοδοι προσδιορισμού της κατάστασης λοίμωξης από φυματίωση (ΤΒ) σε ένα άτομο οι οποίες περιλαμβάνουν: (i) παροχή ενός δείγματος το οποίο περιλαμβάνει Τ-κύτταρα˙ (ii) έκθεση του δείγματος του (i) σε ένα ή περισσότερα ΤΒ αντιγόνα˙ (iii) ταυτοποίηση Τ-κυττάρων στο δείγμα τα οποία είναι CD4 θετικά και (a) εκκρίνουν TNF-α χωρίς έκκριση IFN-γ˙ ή (b) εκκρίνουν IFN-γ χωρίς έκκριση TNF-a˙ (iv) ταυτοποίηση εκείνων των κυττάρων του (iii) τα οποία είναι επίσης CCR7 και, CD127 αρνητικά˙ και κατ' επιλογή (v) υπολογισμό των κυττάρων τα οποία ταυτοποιήθηκαν στο (iv) ως ένα ποσοστό εκείνων τα οποία ταυτοποιήθηκαν στο (iii)˙ όπου η ταυτοποίηση κυττάρων στο (iv) και/ή το ποσοστό Τ-κυττάρων που υπολογίστηκε στο (v) συσχετίζεται με την κατάσταση ΤΒ λοίμωξης του ατόμου, και όπου τα στάδια (iii) κα (iv) μπορεί να πραγματοποιηθούν είτε διαδοχικά είτε ταυτόχρονα. Επίσης παρέχονται συνθέσεις κα κυτία για χρήση σε τέτοιες μεθόδους.
CY20181100387T 2013-09-04 2018-04-10 Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση CY1120220T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1315748.2A GB201315748D0 (en) 2013-09-04 2013-09-04 Biological methods and materials for use therein
PCT/GB2014/052667 WO2015033136A1 (en) 2013-09-04 2014-09-04 Methods and kits for determining tuberculosis infection status

Publications (1)

Publication Number Publication Date
CY1120220T1 true CY1120220T1 (el) 2018-12-12

Family

ID=49397285

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100387T CY1120220T1 (el) 2013-09-04 2018-04-10 Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση

Country Status (12)

Country Link
US (3) US10041944B2 (el)
EP (1) EP3042199B1 (el)
CY (1) CY1120220T1 (el)
DK (1) DK3042199T3 (el)
ES (1) ES2665605T3 (el)
GB (1) GB201315748D0 (el)
HU (1) HUE038739T2 (el)
LT (1) LT3042199T (el)
NO (1) NO3042199T3 (el)
PL (1) PL3042199T3 (el)
PT (1) PT3042199T (el)
WO (1) WO2015033136A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315748D0 (en) * 2013-09-04 2013-10-16 Imp Innovations Ltd Biological methods and materials for use therein
CN107202882B (zh) * 2016-03-17 2019-02-22 广东体必康生物科技有限公司 Rv0440蛋白在诊断潜伏性/活动性肺结核中的用途
ES2950436T3 (es) * 2016-12-14 2023-10-10 Becton Dickinson Co Métodos y composiciones para obtener una valoración de tuberculosis en un sujeto
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CA3065950A1 (en) * 2017-06-03 2018-12-06 Flowmetric Life Sciences, Inc. Flow cytometry system and methods for the diagnosis of infectious disease
CN111337681A (zh) * 2020-03-20 2020-06-26 上海东方肝胆外科医院 评估肝细胞癌预后的标志物、试剂盒及方法
WO2023170189A1 (en) * 2022-03-09 2023-09-14 Fundacio Privada Institut De Recerca De La Sida-Caixa Boosted immune monitoring methods for assaying antigen-specific t cell responses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364869B2 (en) * 2003-07-29 2008-04-29 The J. David Gladstone Institutes Method of detecting antigen-specific T lymphocytes
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
US20090011426A1 (en) 2004-08-19 2009-01-08 Mackintosh James A Methods of Diagnosis and Treatment of M.Tuberculosis Infection and Reagents Therefor
ES2534428T3 (es) 2005-07-26 2015-04-22 Rutgers, The State University Of New Jersey Perfiles de anticuerpos específicos de un estado tuberculoso
CA2644338A1 (en) 2006-03-02 2007-09-07 The Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
GB0605474D0 (en) 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
GB0708874D0 (en) 2007-05-08 2007-06-13 Univ The Of Birmingham Assay for detecting mycrobacterial infection
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DE102007052518A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh Verfahren zur in vitro-Diagnose und/oder in vitro- Therapieverfolgung von Infektionen
WO2009143565A1 (en) 2008-05-26 2009-12-03 Tyrian Diagnostics Limited Method of diagnosis of infection by mycobacteria and reagents therefor
US20110129817A1 (en) 2009-11-30 2011-06-02 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
AU2009262112A1 (en) 2008-06-25 2009-12-30 Baylor Research Institute Blood transcriptional signature of mycobacterium tuberculosis infection
WO2010070581A1 (en) 2008-12-15 2010-06-24 University Of Cape Town Method and device for diagnosing tuberculosis
US20130018178A1 (en) 2009-06-22 2013-01-17 Px Therapeutics Method for the purification of hbha
US8058022B2 (en) 2009-07-27 2011-11-15 Indian Institute Of Science Diagnosis and monitoring of mycobacterium tuberculosis infection
US20110070599A1 (en) 2009-09-18 2011-03-24 Becton, Dickinson And Company Method for Screening of Active Tuberculosis
WO2011044508A1 (en) 2009-10-08 2011-04-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers for prognoses of pulmonary diseases
WO2011113953A1 (en) 2010-03-19 2011-09-22 Red Flag Diagnostics Gmbh In vitro process for the quick determination of a patient's status relating to infection with mycobacterium tuberculosis
CA2860056A1 (en) 2010-12-23 2012-06-28 Centre Hospitalier Universitaire Vaudois Methods for differentiating between disease states of mycobacterium tuberculosis infection
US20150329895A1 (en) * 2012-01-31 2015-11-19 Advanced Medical Research Institute Of Canada Methods of Determining Cell Mediated Response
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
GB201315748D0 (en) * 2013-09-04 2013-10-16 Imp Innovations Ltd Biological methods and materials for use therein

Also Published As

Publication number Publication date
US20180313835A1 (en) 2018-11-01
US20210164979A1 (en) 2021-06-03
LT3042199T (lt) 2018-06-11
PT3042199T (pt) 2018-04-17
US10883990B2 (en) 2021-01-05
WO2015033136A1 (en) 2015-03-12
US10041944B2 (en) 2018-08-07
PL3042199T3 (pl) 2018-07-31
NO3042199T3 (el) 2018-06-09
US20160195529A1 (en) 2016-07-07
GB201315748D0 (en) 2013-10-16
HUE038739T2 (hu) 2018-11-28
US11204352B2 (en) 2021-12-21
EP3042199B1 (en) 2018-01-10
DK3042199T3 (en) 2018-04-23
ES2665605T3 (es) 2018-04-26
EP3042199A1 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
CY1120220T1 (el) Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
CY1124717T1 (el) Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων
CR20240116A (es) RECEPTORES QUIMÉRICOS DE FLT3 Y MÉTODOS DE USO DE LOS MISMOS (Divisional 2018-518)
CY1119763T1 (el) Υποδοχεας ουρων για γυναικες
MX2020001752A (es) Anticuerpos anti-cd3 y metodos de uso.
AR110645A1 (es) Anticuerpos anti-hla-g y uso de los mismos
AR102517A1 (es) Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso
TR201904270T4 (tr) Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller.
MX2018004206A (es) Metodos para diagnosticar enfermedades infecciosas utilizando medios de adsorcion.
MX2016002166A (es) Anticuerpos.
BR112017022329A2 (pt) métodos para detectar aglutinação e composições para uso na prática do mesmo
CY1115624T1 (el) Μεθοδος ανιχνευσης σε καποιο βιολογικο δειγμα των ειδικων αντισωματων για τα αβ
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
CL2024000180A1 (es) Composiciones y métodos para tratar la endometriosis.
MY181007A (en) Scale drop disease (sdd) causative virus and derivatives thereof
MX2022008298A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
MX2016017136A (es) Composiciones y metodos para detectar pegivirus 2 de humano (hpgv-2).
AR085200A1 (es) MEJORA EN LAS RESPUESTAS ESPECIFICAS A PATOGENOS DE LAS CELULAS DE MEMORIA Th17
CY1121482T1 (el) Ευαισθητη πολυπλεκτικη ανοσοδοκιμασια για τους διαλυτους υποδοχεις των αυξητικων παραγοντων των ινοβλαστων
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus
WO2015061610A3 (en) Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
MX2016015531A (es) Ensayo de inflamacion oral.
UY35343A (es) Formulaciones y procedimientos para la producción de proteína recombinante aumentada
MX2021015057A (es) Anticuerpos anti-talen y usos de los mismos.